Up to eleven percent of women of reproductive age could have endometriosis, an undiagnosed painful condition that makes the menstrual cycle harder and is linked to infertility. It’s caused by uterine tissue growth outside of the uterus and there is no cure. An injection therapy became...
You are here
Neurocrine Biosciences, Inc.
Company Information
Address
Neurocrine Biosciences, Inc.
12790 El Camino Real
San Diego, CA
92130
United States
Information
UEI: N/A
# of Employees: N/A
Ownership Information
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
CRF-TYPE-2 RECEPTOR ANTAGONISTS FOR ANXIETY
Amount: $133,540.00DESCRIPTION (provided by applicant): Since the CRF2 receptor was cloned in 1995, relatively little has been learned about its functional biology due primarily to the lack of pharm ...
SBIRPhase I2002Department of Health and Human Services National Institutes of Health -
Novel Non-Peptide Antagonists of the GnRH Receptor
Amount: $471,580.00DESCRIPTION (provided by applicant): Prostate cancer, breast cancer, endometriosis and uterine fibroids are fairly common and serious diseases in men and women. Their etiology ...
SBIRPhase II2001Department of Health and Human Services National Institutes of Health -
Novel Non-Peptide Antagonists of the GnRH Receptor
Amount: $0.00DESCRIPTION (provided by applicant): Prostate cancer, breast cancer, endometriosis and uterine fibroids are fairly common and serious diseases in men and women. Their etiology ...
SBIRPhase I2001Department of Health and Human Services National Institutes of Health -
Hypocretins and Their Role in the Control of Sleep
Amount: $117,853.00DESRIPTION: (Adapted from the Applicant?s Abstract) Insomnia is one of the more prevalent sleep disorders in the US, affecting about 10 percent of the population. Other sleep disorders include obstruc ...
STTRPhase I2001Department of Health and Human Services National Institutes of Health -
Melanocortin-4 Receptor Antagonists
Amount: $207,018.00DESCRIPTION (provided by applicant): The long term objective of this research is to develop small molecule antagonists of the melanocortin-4 receptor (MC4-R) as therapeutic agents for the ...
SBIRPhase I2001Department of Health and Human Services National Institutes of Health -
NOVEL NON-PEPTIDE ANTAGONIST OF THE MCH RECEPTOR
Amount: $138,733.00VivaScan has developed and successfully tested the Optical Bridg(TM) which uniquely nulls out the background, overcoming a major bottleneck in noninvasive blood glucose optical measurements. However, ...
SBIRPhase I2001Department of Health and Human Services National Institutes of Health -
N/A
Amount: $0.00N/A
SBIRPhase I2000Department of Health and Human Services National Institutes of Health -
N/A
Amount: $635,649.00N/A
SBIRPhase II2000Department of Health and Human Services National Institutes of Health -
N/A
Amount: $99,390.00N/A
SBIRPhase I2000Department of Health and Human Services National Institutes of Health -
N/A
Amount: $99,931.00N/A
SBIRPhase I2000Department of Health and Human Services National Institutes of Health
